Half Year 2024 Circio Holding ASA Earnings Call TranscriptAug 29, 2024kr1.35 (+3.86%)Earnings- Q4 2022 Targovax ASA Earnings Call TranscriptFeb 16, 2023kr31.09 (+3.35%)Earnings
- Q3 2022 Targovax ASA Earnings Call TranscriptNov 03, 2022kr34.41 (-2.35%)Earnings
- Q2 2022 Targovax ASA Earnings Call TranscriptAug 18, 2022kr42.58 (-8.06%)Earnings
- Q1 2022 Targovax ASA Earnings Call TranscriptMay 12, 2022kr44.12 (-4.97%)Earnings
- Q4 2021 Targovax ASA Earnings Presentation TranscriptFeb 17, 2022
- Q3 2021 Targovax ASA Earnings Call TranscriptNov 04, 2021kr125.93 (-6.31%)Earnings
- Q2 2021 Targovax ASA Earnings Call TranscriptAug 18, 2021kr167.1 (-5.48%)Earnings
- Q1 2021 Targovax ASA Earnings Call TranscriptMay 06, 2021kr179.21 (-4.39%)Earnings
- Targovax ASA Corporate Analyst Meeting TranscriptFeb 18, 2021
- Targovax ASA - Special Call TranscriptDec 02, 2020
- Q3 2020 Targovax ASA Earnings Call TranscriptNov 05, 2020kr166.13 (+9.94%)Earnings
- Q2 2020 Targovax ASA Earnings Call TranscriptAug 20, 2020kr159.35 (-2.52%)Earnings
- Targovax ASA Corporate Analyst Meeting TranscriptJun 25, 2020
- Q1 2020 Targovax ASA Earnings Call TranscriptMay 07, 2020kr197.61 (-7.80%)Earnings
- Q4 2019 Targovax ASA Earnings Call TranscriptMar 11, 2020kr106.56 (-10.02%)Earnings
- Targovax ASA - Pre Recorded Special Call TranscriptJan 21, 2020
- Targovax ASA - Special Call TranscriptNov 15, 2019
- Q3 2019 Targovax ASA Earnings Call TranscriptNov 07, 2019kr125.69 (+2.77%)Earnings
- Q2 2019 Targovax ASA Earnings Call TranscriptAug 22, 2019kr134.89 (-4.30%)Earnings
- Q1 2019 Targovax ASA Earnings Call TranscriptMay 09, 2019kr153.78 (-3.79%)Earnings
Q3 2021 Targovax ASA Earnings Call Transcript
Welcome to Targovax and our report and presentation of our third quarter results. My name is Erik Digman Wiklund, and I was recently appointed CEO of Targovax.
So first of all, let me remind you of who we are and what we do. We are a Norway-based immuno-oncology biotech, and our focus is on developing immune activators. Our lead product candidate is called ONCOS-102. And this is a novel immune activator, which has demonstrated clinical efficacy in several hard-to-treat solid tumors. We have confirmed the mode of action of ONCOS-102 in a clinical setting and demonstrated broad and powerful immune responses that makes ONCOS-102 a very attractive combination partner for other immunotherapies in difficult to treat solid tumors.
We are currently preparing for the next steps of our development program, which will be a PD-1 refractory melanoma in a broader platform trial where we are going to assess multiple combinations in parallel. ONCOS-102 is protected by both method of use and composition of matter patents, and we have orphan drug designation in 3
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
